keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy-induced thrombocytopenia

keyword
https://www.readbyqxmd.com/read/28630120/selinexor-induced-thrombocytopenia-results-from-inhibition-of-thrombopoietin-signaling-in-early-megakaryopoiesis
#1
Kellie R Machlus, Stephen K Wu, Prakrith Vijey, Thomas S Soussou, Zhi-Jian Liu, Eran Shacham, T J Unger, Trinayan Kashyap, Boris Klebanov, Martha Sola-Visner, Marsha Crochiere, Joseph E Italiano, Yosef Landesman
Selinexor is the first oral Selective Inhibitor of Nuclear Export compound tested for cancer treatment. Selinexor has demonstrated a safety therapy profile with broad antitumor activity against solid and hematological malignancies in phases 2 and 3 clinical trials (NCT03071276, NCT02343042, NCT02227251, NCT03110562, NCT02606461). While selinexor shows promising efficacy, its primary adverse effect is high-grade thrombocytopenia. Therefore, we aimed to identify the mechanism of selinexor-induced thrombocytopenia to relieve it and improve its clinical management...
June 19, 2017: Blood
https://www.readbyqxmd.com/read/28494179/predictive-biomarkers-for-triple-negative-breast-cancer-treated-with-platinum-based-chemotherapy
#2
Juan Jin, Wenwen Zhang, Wenfei Ji, Fang Yang, Xiaoxiang Guan
Treatment of triple negative breast cancer (TNBC) has been a big challenge since it is defined. To date, platinum-based chemotherapy has played a significant role in the treatment of TNBC patients. However, some patients do not respond to platinum salts or gradually develop chemoresistance, resulting in little effect, or even some adverse effects. Here, we review numerous preclinical and clinical investigations to summarize possible mechanisms and potential predictive biomarkers of platinum in TNBC. The homologous recombination deficiency (HRD) resulting from the loss of BRCA function is the main rationale of platinum efficacy in TNBC...
May 11, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28489759/shen-cao-granules-formulated-based-on-traditional-chinese-medicine-alleviates-bone-marrow-suppression-caused-by-platinum-based-anticancer-reagents
#3
Chunfeng Yu, Zhonghua Jiang, Aihua Hou, Yuejun Mu, Wei Liu, Song Tan
BACKGROUND: The aim of this study was to evaluate effects of Shen-Cao granules for the prevention of thrombocytopenia caused by anticancer chemotherapy. METHODS: In this prospective study, a total of 200 patients with various malignant tumors were enrolled and evenly divided into a Shen-Cao granule treatment (n = 100) and a control group (n = 100). After 2 cycles chemotherapy with any combination of platinum-based drugs (cisplatin, carboplatin, and nedaplatin), the blood platelet (PLT) counts, levels of the PLT production regulator thrombopoietin (TPO), PLT aggregation rates, and the PLT activation marker CD62P expressions were monitored for 2 weeks...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28485375/impact-of-nadph-oxidase-functional-polymorphisms-in-acute-myeloid-leukemia-induction-chemotherapy
#4
J E Megías-Vericat, P Montesinos, M J Herrero, F Moscardó, V Bosó, L Rojas, D Martínez-Cuadrón, R Rodríguez-Veiga, L Sendra, J Cervera, J L Poveda, M Á Sanz, S F Aliño
Efficacy and toxicity of anthracycline treatment in acute myeloid leukemia (AML) is mediated by reactive oxygen species (ROS). NADPH oxidase is the major endogenous source of ROS and a key mediator of oxidative cardiac damage. The impact of NADPH oxidase polymorphisms (CYBA:rs4673, NCF4:rs1883112, RAC2:rs13058338) was evaluated in 225 adult de novo AML patients. Variant alleles of NCF4 and RAC2 were related to higher complete remission (P=0.035, P=0.016), and CYBA homozygous variant showed lower overall survival with recessive model (P=0...
May 9, 2017: Pharmacogenomics Journal
https://www.readbyqxmd.com/read/28472560/nedaplatin-and-irinotecan-with-concurrent-thoracic-radiotherapy-followed-by-docetaxel-consolidation-in-patients-with-locally-advanced-non-small-cell-lung-cancer
#5
Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada, Yuko Nakayama
OBJECTIVE: We conducted a phase II study of nedaplatin (NP) and irinotecan (CPT) with concurrent thoracic radiotherapy (TRT) followed by docetaxel for locally advanced non-small cell lung cancer (NSCLC) to determine the safety and efficacy of the treatment. Patients with stage IIIA or IIIB NSCLC were treated with 3 cycles of chemotherapy comprising NP at 50 mg/m(2) and CPT at 50 mg/m(2) on days 1 and 8 every 4 weeks with concurrent TRT (2 Gy/day, total 66 Gy) followed by 3 cycles of docetaxel at 60 mg/m(2) on day 1 every 3 weeks...
May 2017: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/28450306/osteoblasts-support-megakaryopoiesis-through-production-of-interleukin-9
#6
Min Xiao, Yongkui Wang, Chen Tao, Zhenyu Wang, Jun Yang, Zhenguo Chen, Zhipeng Zou, Mangmang Li, Anling Liu, Chunhong Jia, Bin Huang, Bo Yan, Pinglin Lai, Changhai Ding, Daozhang Cai, Guozhi Xiao, Yu Jiang, Xiaochun Bai
Severe thrombocytopenia is a significant challenge in patients undergoing myelosuppressive chemotherapy for malignancies. Understanding the biology of platelet-producing megakaryocytes development in the bone marrow microenvironment may facilitate the development of novel therapies to stimulate platelet production and prevent thrombocytepenia. We report here that osteoblasts supported megakaryopoiesis by secreting interleukin-9 (IL-9), which stimulated IL-9 receptor (IL-9R)/Stat3 signaling in promoting megakaryopoiesis...
April 27, 2017: Blood
https://www.readbyqxmd.com/read/28439927/antithrombotic-therapy-and-platelet-transfusions-in-hematologic-malignancy-patients-presenting-chemotherapy-induced-thrombocytopenia-a-french-survey
#7
Emilie Chalayer, Doriane Cavalieri, Jean Alain Martignoles, Alexis Genthon, Emmanuelle Tavernier, Bernard Tardy
BACKGROUND: Patients with hematologic malignancies are at high risk for both thrombosis and bleeding. During the prolonged periods of thrombocytopenia experienced by patients who are receiving intensive chemotherapy, clinicians often hesitate to prescribe any protection against thrombosis. In case of anticoagulant prescription, it is the prescribers' responsibility to weigh risks and benefits for each patient. Current guidelines exist but do not take into account types of thrombosis, patients' comorbidities, or previous bleeding events...
April 25, 2017: Transfusion
https://www.readbyqxmd.com/read/28424440/gemcitabine-induced-coronary-vasospasm-a-case-report
#8
Mahmut Tuna Katırcıbaşı, Aynur Eken
Gemcitabine is a chemotherapy drug. It is a nucleoside analogue that is usually well tolerated by patients, with myelosuppression (especially thrombocytopenia) as dose-limiting side effect. Other mild to moderate side effects include alopecia, vomiting, nausea, rash, and fever. Coronary ischemia is the most common cardiotoxic effect of gemcitabine, which is due to its antimetabolites. While underlying cause of coronary ischemia following use of gemcitabine is uncertain, endothelial dysfunction and coronary thrombosis are potential explanations...
March 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28395880/treatment-of-metastatic-uveal-melanoma-with-adoptive-transfer-of-tumour-infiltrating-lymphocytes-a-single-centre-two-stage-single-arm-phase-2-study
#9
Smita S Chandran, Robert P T Somerville, James C Yang, Richard M Sherry, Christopher A Klebanoff, Stephanie L Goff, John R Wunderlich, David N Danforth, Daniel Zlott, Biman C Paria, Arvind C Sabesan, Abhishek K Srivastava, Liqiang Xi, Trinh H Pham, Mark Raffeld, Donald E White, Mary Ann Toomey, Steven A Rosenberg, Udai S Kammula
BACKGROUND: Uveal melanoma is a rare tumour with no established treatments once metastases develop. Although a variety of immune-based therapies have shown efficacy in metastatic cutaneous melanoma, their use in ocular variants has been disappointing. Recently, adoptive T-cell therapy has shown salvage responses in multiple refractory solid tumours. Thus, we sought to determine if adoptive transfer of autologous tumour-infiltrating lymphocytes (TILs) could mediate regression of metastatic uveal melanoma...
April 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28358421/extravasated-platelet-aggregation-in-the-livers-of-rats-with-drug%C3%A2-induced-hepatic-sinusoidal-obstruction-syndrome
#10
Miki Hirata, Hidehiro Tajima, Tomoharu Miyashita, Takashi Miyata, Shinichi Nakanuma, Isamu Makino, Hironori Hayashi, Katsunobu Oyama, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Hiroki Nakata, Shoichi Iseki, Shinichi Harada, Tomohiko Wakayama, Tetsuo Ohta
Oxaliplatin-based chemotherapy plays an important role in the treatment of colorectal liver metastases. Oxaliplatin, however, causes sinusoidal obstruction syndrome (SOS), which is characterized by portal hypertension, splenomegaly, thrombocytopenia, and liver dysfunction. SOS is diagnosed histopathologically by disruption of the sinusoidal endothelium, collagen deposition, fibrosis especially around zone 3, dilatation of the sinusoidal space and congestion. This study assessed the characteristics of a rat model of SOS...
May 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28160575/safety-and-efficacy-of-bleomycin-pingyangmycin-containing-chemotherapy-regimens-for-malignant-germ-cell-tumor-patients-in-the-female-genital-system
#11
Qianying Zhao, Dongyan Cao, Mei Yu, Jiaxin Yang, Yongjian Liu, Yang Xiang, Ming Wu, Lingya Pan, Jinghe Lang, Kaifeng Xu, Jiangna Han, Keng Shen
OBJECTIVES: To comprehensively evaluate the safety and effectiveness of bleomycin/pingyangmycin-containing chemotherapy for female patients with malignant germ cell tumors in their genital system; to assess the diagnostic value of pulmonary function tests for bleomycin-induced pulmonary toxicity. METHODS: Data from a cohort of 120 patients, collected across 25 years, was reviewed. Chemotherapy-related adverse events were routinely monitored. Pulmonary toxicity was diagnosed and graded according to serial pulmonary function testing results, and potential impact factors were explored...
February 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28152765/evaluation-of-relative-thrombocytopenia-identification-of-neuropathy-and-bleeding-risk-secondary-to-utilization-of-neuromodulating-agents-in-multiple-myeloma-patients-receiving-autologous-stem-cell-transplant-treated-with-melphalan-bortezomib-and-lenalidomide
#12
Joel Marcus, Robyn Jackson, Marco A Ruiz, Ryan Patrick Griffin, Rubina Hafeez Khan
212 Background: Chemotherapy-induced polyneuropathy (CIPN) is a crippling manifestation in multiple myeloma (MM) patients that requires attentiveness to safety and quality of life.(2) Bortezomib, lenalidomide, and melphalan are commonly utilized chemotherapy agents that can cause both CIPN(3,4) and significant myelosuppression. Within this subset of patients we wish to insure efficacy and minimization of neuropathic pain while being mindful of bleeding risks. METHODS: IRB approval was obtained for a retrospective study of patients with MM who received a bone marrow transplant (BMT)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28047407/su-f-t-110-lkb-modeling-of-acute-hematologic-toxicity-in-rectal-cancer
#13
H Deng, K Cheng, X Wan
PURPOSE: To investigate dosimetric parameters correlated with acute hematologic toxicity (HT) in patients with rectal cancer treated with IMRT and concurrent chemotherapy. METHODS: We analyzed 127 rectal cancer patients receiving IMRT and concurrent chemotherapy. Whole pelvic bone marrow (PBM) was contoured for each patient including lumbosacral spine (LSSP), ilium and lower pelvic (LP). The equivalent uniform dose (EUD) of each region and the PBM were calculated...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28001189/acute-myeloid-leukemia-after-kidney-transplantation-a-case-report-and-literature-review
#14
Francesca Cardarelli, Vanesa Bijol, Anil Chandraker, Cindy Varga, Leonardo V Riella
The incidence of malignancy is greater in kidney transplant recipients compared to the general population, though the higher risk is not equally distributed to all types of cancers. In face of the increased longevity of renal transplant recipients, certain cancers, such as acute leukemias, are becoming more prevalent. Acute myeloid leukemia (AML) typically presents with cytopenias and infections, both common findings after kidney transplantation. Therefore, the diagnosis of AML may be initially overlooked in these patients...
December 2016: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/27986986/a-pharmacokinetic-study-of-lipegfilgrastim-in-children-with-ewing-family-of-tumors-or-rhabdomyosarcoma
#15
MULTICENTER STUDY
Margarita B Belogurova, Zoryana P Kizyma, Miklós Garami, Mónika Csóka, Michael J Lamson, Anton Buchner, Peter Bias, Andreas Lammerich
PURPOSE: Neutropenia is a common complication from chemotherapy, limiting optimal dosing and treatment. Lipegfilgrastim is a long-acting granulocyte colony-stimulating factor developed for the management of chemotherapy-induced neutropenia. The objectives of this phase 1, multinational, open-label, single-arm study were to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a single body weight-adjusted dose of lipegfilgrastim and to evaluate the efficacy, safety, and tolerability of the drug in children with Ewing family of tumors or rhabdomyosarcoma treated with myelosuppressive chemotherapy...
January 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27956157/ibrutinib-for-patients-with-rituximab-refractory-waldenstr%C3%A3-m-s-macroglobulinaemia-innovate-an-open-label-substudy-of-an-international-multicentre-phase-3-trial
#16
MULTICENTER STUDY
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T Heffner, Chaim Shustik, Ramón García-Sanz, Robert F Cornell, Carlos Fernández de Larrea, Jorge J Castillo, Miquel Granell, Marie-Christine Kyrtsonis, Veronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh, Jianling Li, Thorsten Graef, Elizabeth Bilotti, Steven Treon, Christian Buske
BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease. METHODS: This multicentre, open-label substudy was done at 19 sites in seven countries in adults aged 18 years and older with confirmed Waldenström's macroglobulinaemia, refractory to rituximab and requiring treatment...
February 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27668103/immune-thrombocytopenia-in-a-child-with-t-cell-lymphoblastic-lymphoma
#17
Kayo Tokeji, Sachi Sakaguchi, Tomoko Kurimoto, Junya Fujimura, Toshiaki Shimizu
We describe the case of a 13-year-old boy who presented with persistent thrombocytopenia during maintenance chemotherapy with mercaptopurine and methotrexate for T cell lymphoblastic lymphoma. He was diagnosed with immune thrombocytopenia (ITP) after thorough investigations for the relapse of lymphoma and was successfully treated with immunoglobulin and steroids. ITP is known to be associated with chronic lymphocytic leukemia, Hodgkin lymphoma, and various types of non-Hodgkin lymphoma but rarely with T cell non-Hodgkin lymphoma or in children...
2016: Case Reports in Hematology
https://www.readbyqxmd.com/read/27639907/-rituximab-induced-acute-thrombocytopenia-in-a-patient-with-chronic-lymphocytic-leukemia
#18
M Bobot, M Benzaquen, F Rouby, D Lebowitz, J Serratrice, J-M Durand
INTRODUCTION: Rituximab is a chimeric anti-CD20 monoclonal antibody generally well tolerated. However, a severe but rare rituximab-related immune-toxic syndrome, associating fever, chills and thrombocytopenia can occur shortly after the infusion. CASE REPORT: We report a case of severe acute rituximab-induced thrombocytopenia with favorable outcome in a patient with chronic lymphocytic leukemia and discuss the possible underlying mechanisms. CONCLUSION: Despite the potential initial severity of rituximab-induced thrombocytopenia in CLL, chemotherapy should not be discontinued; tolerance might increase as the hematologic disorder is controlled...
May 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27456925/factors-influencing-the-efficacy-of-platelet-transfusions-in-acute-leukemia
#19
A Wahlin, L Eliasson, H Jonsson
The efficacy of platelet transfusions was evaluated in a prospective study of 37 patients with acute leukemia. The patients received 495 platelet transfusions for chemotherapy-induced thrombocytopenia. Life table analysis was found to be useful for prediction of the platelet level after transfusion. Efficacy was positively correlated with platelet content in the concentrate, and inversely correlated with bleeding. Fever, contamination of the: concentrate by leukocytes, or previous platelet transfusions were not found to have any significant influence on the efficacy, as analyzed by multiple regression...
1990: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27425556/gradual-thrombocytopenia-induced-by-long-term-trastuzumab-exposure
#20
M Miarons, M Velasco, L Campins, S Fernández, T Gurrera, L Lopez-Viaplana
WHAT IS KNOWN AND OBJECTIVE: Unexplained thrombocytopenia is a common clinical problem, and the possibility of drug-induced thrombocytopenia must be considered. Moreover, chemotherapy agents are known to typically cause thrombocytopenia by suppressing haematopoiesis, but they can also cause immune thrombocytopenia in which the mechanism involves antibody-mediated platelet destruction. CASE DESCRIPTION: We report a case of severe thrombocytopenia related to trastuzumab administration in which the patient exhibits a slow drift downward in platelet counts with repeated cycles of trastuzumab...
October 2016: Journal of Clinical Pharmacy and Therapeutics
keyword
keyword
115055
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"